Beauty Health Sets Q4 2025 Earnings Release for March 12

GlobeNewswire Inc.GlobeNewswire Inc.
|||1 min read
Key Takeaway

Beauty Health (SKIN) will release Q4 2025 earnings March 12, 2026, followed by an investor call at 4:30 p.m. ET to discuss financial performance and guidance.

Beauty Health Sets Q4 2025 Earnings Release for March 12

The Beauty Health Company (NASDAQ: SKIN) announced it will release its fourth quarter and full year 2025 financial results on March 12, 2026. The announcement follows the company's standard reporting schedule for concluding its fiscal year.

Following the earnings release, the skincare technology company will host an investor conference call at 4:30 p.m. Eastern Time to discuss financial performance and provide guidance to analysts and investors. The Hydrafacial brand operator will use the session to address questions from the investment community regarding its operational and financial developments throughout 2025.

Investors and market participants can anticipate detailed metrics on revenue, profitability, and operational performance during the reporting period. The earnings call will offer insight into Beauty Health's strategic positioning and outlook as the company advances into the new fiscal year.

Source: GlobeNewswire Inc.

Back to newsPublished Feb 26

Related Coverage

GlobeNewswire Inc.

Sika AG Shareholders Approve Board, Boost Dividend to CHF 3.70 Per Share

Sika AG shareholders approved CHF 3.70 dividend and board re-election at 2026 AGM, with company reporting CHF 11.20B sales and 33,700 employees globally.

SXYAY
GlobeNewswire Inc.

17EdTech Posts Narrower Loss Despite Revenue Decline as AI Product Gains Traction

17EdTech reports Q4 revenue growth of 6.4% YoY and significant margin expansion, though full-year revenues declined 44% due to business model shift. New AI product 'Yiqi Aixue' shows strong pre-sale demand.

YQ
The Motley Fool

Slide Insurance Posts $444M Profit on Strong Revenue Growth; Insider Trims Position

Slide Insurance reported $444M net income and $1.16B revenue, up 36% YoY. Director sold $1M in shares via pre-arranged plan while maintaining substantial stake.

SLDE
GlobeNewswire Inc.

IMUNON Sets March 31 Call to Detail 2025 Results, OVATION 3 Trial Progress

$IMNN to discuss 2025 results and OVATION 3 Phase 3 trial progress for IMNN-001 ovarian cancer immunotherapy on March 31, 2026.

IMNN
GlobeNewswire Inc.

Inventiva to Report 2025 Results as MASH Drug Candidate Advances

Inventiva will release 2025 financial results March 30, 2026, while advancing lanifibranor in Phase 3 MASH trials.

IVA
GlobeNewswire Inc.

Inventiva to Report 2025 Results as MASH Drug Candidate Advances in Phase 3

Inventiva to release 2025 financial results March 30, 2026, as its lanifibranor MASH drug advances through Phase 3 clinical trials.

IVA